A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
Public ClinicalTrials.gov record NCT04504916. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of VLS-101 in Patients With Solid Tumors
Study identification
- NCT ID
- NCT04504916
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 102 participants
Conditions and interventions
Conditions
- ER-negative Breast Cancer
- ER-positive Breast Cancer
- Estrogen-receptor-negative Breast Cancer
- Estrogen-receptor-positive Breast Cancer
- Gastric Cancer
- HER2-negative Breast Cancer
- NSCLC
- Non-squamous Non-small-cell Lung Cancer
- PR-negative Breast Cancer
- PR-positive Breast Cancer
- Pancreatic Cancer
- Platinum-resistant Ovarian Cancer
- Progesterone-receptor Negative Breast Cancer
- Progesterone-receptor-positive Breast Cancer
- Triple-negative Breast Cancer
Interventions
- Zilovertamab vedotin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 6, 2020
- Primary completion
- Jun 11, 2023
- Completion
- Jun 11, 2023
- Last update posted
- Nov 9, 2025
2020 – 2023
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Memorial Regional Hospital-Memorial Cancer Institute ( Site 0005) | Hollywood | Florida | 33021 | — |
| AdventHealth Orlando ( Site 0003) | Orlando | Florida | 32804 | — |
| Massachusetts General Hospital ( Site 0017) | Boston | Massachusetts | 02114 | — |
| John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0002) | Hackensack | New Jersey | 07601 | — |
| Memorial Sloan Kettering Cancer Center ( Site 0007) | New York | New York | 10021 | — |
| MD Anderson ( Site 0001) | Houston | Texas | 77030 | — |
| The University of Texas Health Science Center at San Antonio ( Site 0004) | San Antonio | Texas | 78229 | — |
| Swedish Medical Center ( Site 0008) | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04504916, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2025 · Synced May 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04504916 live on ClinicalTrials.gov.